BRAINTREE, Mass., and WEST CHESTER, Pa., July 10 / -- Haemonetics Corporation, a global leader in blood management solutions, announced today that it has acquired Infonale, Inc. for $1.3 million in cash plus contingent consideration based upon future operating performance. Infonale is a leading developer of IT software and consulting services for optimizing hospital blood use and management.
At its recent May shareholders' meeting, Haemonetics announced its vision to bring to its blood collection and hospital customers a suite of blood management solutions that can reduce costs and improve clinical outcomes. Infonale's proprietary software, clinical database, and consulting services support this vision and complement Haemonetics' expanding portfolio into hospital surgical markets.
Infonale provides hospitals with consulting services, backed by innovative IT software, that track blood use data, including total charges by physician, patient length of stay comparisons, and diagnosis-related group ("DRG") care patterns. The Infonale systems have shown that hospitals can improve patient outcomes and save costs by steering blood management policies and practices to evidence-based best practices. Haemonetics estimates this market at greater than $35 million.
Brad Nutter, Haemonetics' President and CEO, said, "Several years ago, Haemonetics acquired 5D Information Management to provide information technology solutions to our plasma customers. In February of this year, we acquired Information Data Management which strengthens our information management offering to blood bank customers. So in the blood collection market we have begun to demonstrate that information technology can be a powerful tool to enhance the blood supply chain. Infonale adds IT and service expertise to the hospital markets and will help customers apply the appropriate resources to reduce blood costs and enhance patient care. The acquisition is important to Haemonetics' ongoing transformation to a total blood management solutions company."
Emphasizing the Company's commitment to a total customer value proposition, Tom Lawlor, President of Haemonetics' Patient Division, said, "In the past year, we've introduced four new products that expand Haemonetics' reach in the surgical suite. We've moved to a sales approach based upon a total blood management value proposition. With the Infonale acquisition, we've further strengthened our customer value proposition by providing information critical to optimizing blood use."
F. Curtis Lambert, Infonale's President and CEO, said, "The Haemonetics' brand will enable Infonale to expand its customer base and offer hospitals innovative blood management solutions that can both save costs and improve clinical outcomes for patients."
Infonale's personnel and operations will remain in the Philadelphia area.
Haemonetics (NYSE:HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics' products and markets, visit its web site at www.haemonetics.com/.
Tel. (781) 356-9517
Alternate Tel. (617) 320-2401
FCMN Contact: email@example.com
Source: Haemonetics Corporation
Web site: www.haemonetics.com